The response rate to Amtagvi was higher in patients who had received two or fewer therapies than in those with more heavily ...

Results from a retrospective study found that Amtagvi (lifileucel) achieved a 48.8% objective response rate in patients with ...

Iovance Biotherapeutics’ Amtagvi study data shows 49 per cent response rate for commercialisation: San Carlos, California Thursday, July 17, 2025, 12:00 Hrs [IST] Iovance Biothe ...

(NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today ...

A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 best healthcare penny stocks to buy according to analysts. Goldman Sachs reiterated its “Buy” rating on Iovance’s stock on June 3. The firm ...

Iovance Biotherapeutics, Inc. Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue. Total Product Revenue Guidance of $53-$55 Million for 3Q24 ...

With the notable exceptions of Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY), biotechnology stocks had a rough time attracting investment capital in 2024. Small- and mid-cap biotech ...

Amtagvi is also being evaluated in separate mid-stage studies for cervical and endometrial cancer indications. IOVA’s Zacks Rank. Iovance currently has a Zacks Rank #4 (Sell).

As Amtagvi is made from the living cells of the patient, being a first-line therapy means that the cancer has less time to progress. With less time for the disease to progress and inflict harm, ...

In addition to expanding Amtagvi's reach, Iovance is also working on a next-generation TIL therapy. IOV-4001 will use TILs that don't express programmed cell death protein 1 on their surface.